Dr. Reddy's Laboratories heads into its June 2 results with the same structural divide that has run through this entire preview cycle — short sellers still elevated, options traders still unbothered — though the short side has pulled back further since the last preview.
The borrow market has eased at the margin. Shares short slipped another 1% on May 29 to roughly 19.6 million, retreating from the cycle peak of nearly 19.9 million hit on Wednesday. The one-month build remains steep at nearly 30%, and the ORTEX short score — at 57.0, down fractionally from the 57.3 series high — is still running well above mid-May levels. Availability has continued recovering, now at 59.3%, versus the 31–33% cycle lows seen in the week of May 18–22. With roughly one share available for every one-and-a-half borrowed, the lending pool has loosened meaningfully from its tightest point, and cost to borrow has pulled back to 0.70% from the 0.84% peak — though it remains above the sub-0.60% readings that defined early May.
Options traders remain firmly on the other side of that trade. The put/call ratio held at 0.15 through the weekend, just above the 52-week low of 0.009, and less than half the 20-day average of 0.41. That is a striking call-side skew — a reading this low signals that options flow is dominated by upside positioning rather than downside hedging, the opposite of what the short interest build might suggest. The divergence has now persisted for roughly three weeks without resolution.
Analyst data for the NYSE-listed ADR carries important caveats. The most recent actionable note was an HSBC upgrade — from Hold to Buy with a target of $16.90 — filed in June 2025, now a year old. Barclays has maintained an Overweight rating through multiple target adjustments over recent years, with its most recent note from November 2024. These are too dated to be treated as current guidance, but the directional tilt from both firms was constructive. The regulatory scrutiny angle flagged in recent context notes remains the central bear case: manufacturing compliance risk has weighed on sentiment and margin visibility. Bulls point to a strong dividend track record and a pharma franchise that continues generating cash even as near-term execution risks cloud the outlook. The stock's PE of 22.6x and EV/EBITDA of 13.7x sit at the lower end of their recent ranges, having compressed roughly 3% over the past month.
The June 2 print will test whether the sustained short buildup of recent weeks — now the highest level of the cycle — reflects a well-grounded concern about earnings delivery, or whether options traders' persistent call-side skew is the more accurate read on what the numbers will actually show.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
